Stock Update (NASDAQ:AMGN): U.S. FDA approves Amgen heart failure drug

[Reuters] – U.S. health regulators on Wednesday approved Amgen Inc’s Corlanor to treat patients with chronic heart failure, giving the world’s largest biotechnology company its first cardiovascular medicine product. … Read more on . . . → Read More: Stock Update (NASDAQ:AMGN): U.S. FDA approves Amgen heart failure drug Similar Articles: Company Update (NASDAQ:AMGN): Amgen to appeal rejection of bid to block Novartis biosimilar drug Market Update (NYSE:LLY): FDA approves Boehringer-Lilly drug for type-2 diabetes patients Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival